Search research articles
Contact Us
Filters
Showing results (21-30 of 31) with videos related to
Page
of 4
Sort By:
Cancer Research
|
May 14, 2009
EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma
Bipasha Mukherjee, Brian McEllin, Cristel V Camacho, et al.
Cancer Research
|
November 9, 2006
A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma
Fenghua Liu, Peter J Park, Weil Lai, et al.
Breast (Edinburgh, Scotland)
|
June 25, 2021
Clinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer - A retrospective cohort study
Matthew G Davey, Eoin Kerin, C O'Flaherty, et al.
Advances in Radiation Oncology
|
July 4, 2025
Comparative Outcomes of Standard Radiation Therapy and 5-Fraction Adaptive Stereotactic Radiation Therapy in Newly Diagnosed Glioblastoma: A Propensity Score-Matched Analysis
Michael Dohopolski, Luiza Giuliani Schmitt, Jill de Vis, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 9, 2026
Adaptive MRI-Guided Reirradiation for High-Risk Recurrent Grade 4 Gliomas: Early Clinical Outcomes and Volumetric Response
Luiza Giuliani Schmitt, Michael Dohopolski, Jill de Vis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 13, 2020
Ivosidenib in Isocitrate Dehydrogenase 1<i>-</i>Mutated Advanced Glioma
Ingo K Mellinghoff, Benjamin M Ellingson, Mehdi Touat, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 5, 2006
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors
Hongbin Ji, Xiaojun Zhao, Yuki Yuza, et al.
Neuro-Oncology
|
December 23, 2015
Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma
Macarena I de la Fuente, Robert J Young, Jennifer Rubel, et al.
The Lancet. Oncology
|
November 1, 2025
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial
Timothy F Cloughesy, Martin J van den Bent, Mehdi Touat, et al.
International Journal of Clinical and Health Psychology : IJCHP
|
August 25, 2021
An international study on psychological coping during COVID-19: Towards a meaning-centered coping style
Nikolett Eisenbeck, David F Carreno, Paul T P Wong, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 31) with videos related to
Sort By:
Page
of 4
Cancer Research
|
May 14, 2009
EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma
Bipasha Mukherjee, Brian McEllin, Cristel V Camacho, et al.
Cancer Research
|
November 9, 2006
A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma
Fenghua Liu, Peter J Park, Weil Lai, et al.
Breast (Edinburgh, Scotland)
|
June 25, 2021
Clinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer - A retrospective cohort study
Matthew G Davey, Eoin Kerin, C O'Flaherty, et al.
Advances in Radiation Oncology
|
July 4, 2025
Comparative Outcomes of Standard Radiation Therapy and 5-Fraction Adaptive Stereotactic Radiation Therapy in Newly Diagnosed Glioblastoma: A Propensity Score-Matched Analysis
Michael Dohopolski, Luiza Giuliani Schmitt, Jill de Vis, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 9, 2026
Adaptive MRI-Guided Reirradiation for High-Risk Recurrent Grade 4 Gliomas: Early Clinical Outcomes and Volumetric Response
Luiza Giuliani Schmitt, Michael Dohopolski, Jill de Vis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 13, 2020
Ivosidenib in Isocitrate Dehydrogenase 1<i>-</i>Mutated Advanced Glioma
Ingo K Mellinghoff, Benjamin M Ellingson, Mehdi Touat, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 5, 2006
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors
Hongbin Ji, Xiaojun Zhao, Yuki Yuza, et al.
Neuro-Oncology
|
December 23, 2015
Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma
Macarena I de la Fuente, Robert J Young, Jennifer Rubel, et al.
The Lancet. Oncology
|
November 1, 2025
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial
Timothy F Cloughesy, Martin J van den Bent, Mehdi Touat, et al.
International Journal of Clinical and Health Psychology : IJCHP
|
August 25, 2021
An international study on psychological coping during COVID-19: Towards a meaning-centered coping style
Nikolett Eisenbeck, David F Carreno, Paul T P Wong, et al.
Page
of 4